Compare TLSI & OPBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TLSI | OPBK |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.0M | 230.9M |
| IPO Year | 2020 | 2018 |
| Metric | TLSI | OPBK |
|---|---|---|
| Price | $3.65 | $15.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $10.40 | ★ $17.75 |
| AVG Volume (30 Days) | ★ 295.8K | 27.0K |
| Earning Date | 11-10-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 3.83% |
| EPS Growth | N/A | ★ 23.74 |
| EPS | N/A | ★ 1.02 |
| Revenue | ★ $45,151,000.00 | $3,204,000.00 |
| Revenue This Year | $17.65 | $9.63 |
| Revenue Next Year | $40.27 | $10.79 |
| P/E Ratio | ★ N/A | $14.33 |
| Revenue Growth | ★ 53.41 | N/A |
| 52 Week Low | $2.20 | $12.41 |
| 52 Week High | $7.95 | $16.83 |
| Indicator | TLSI | OPBK |
|---|---|---|
| Relative Strength Index (RSI) | 30.68 | 49.57 |
| Support Level | $3.05 | $14.81 |
| Resistance Level | $3.68 | $15.60 |
| Average True Range (ATR) | 0.21 | 0.28 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 11.11 | 47.42 |
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
OP Bancorp operates its commercial community banking activities through Open Bank its wholly owned banking subsidiary. It provides commercial banking services to small and medium-sized businesses, their owners, and retail customers, with a focus on the Korean-American community. The bank currently operate twelve full service branches: nine branches across Los Angeles and Orange Counties in California, as well as one branch each in Santa Clara, California; Carrollton, Texas; and Las Vegas, Nevada. Additionally, it maintains five loan production offices located in Pleasanton, California; Atlanta, Georgia; Aurora, Colorado; Lynnwood, Washington; and Fairfax, Virginia. Substantially all its business activities are conducted through the Bank.